Comparative Pharmacology
Head-to-head clinical analysis: CYANOKIT versus PRALIDOXIME CHLORIDE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYANOKIT versus PRALIDOXIME CHLORIDE AUTOINJECTOR.
CYANOKIT vs PRALIDOXIME CHLORIDE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin, a form of vitamin B12, acts as a scavenger of cyanide ions by binding with them to form cyanocobalamin, which is then excreted in urine. It has a higher affinity for cyanide than cytochrome c oxidase, thereby restoring mitochondrial function.
Reactivates acetylcholinesterase inhibited by organophosphate poisoning by binding to the organophosphate moiety.
5 g intravenous infusion over 15 minutes for adults and pediatric patients weighing >=40 kg. A second dose of 5 g may be administered if needed based on clinical response.
1-2 g IV or IM, repeat after 1 hour if muscle fasciculations persist, then every 6-12 hours as needed. Administer as a 5% solution (1g in 20mL) over 5-10 minutes IV; IM into deltoid or anterolateral thigh.
None Documented
None Documented
The terminal elimination half-life of hydroxocobalamin is approximately 24-28 hours in healthy adults; in cyanide poisoning, the half-life may be prolonged due to reversible binding to cyanide.
Terminal elimination half-life is approximately 1.2-2.5 hours in adults with normal renal function. In organophosphate poisoning, prolonged half-life may occur due to redistribution or renal impairment; clinical context: requires repeated dosing or continuous infusion to maintain therapeutic concentrations.
Primarily renal elimination as hydroxocobalamin and cyanocobalamin; >90% of an intravenous dose is excreted in urine within 72 hours, with the remainder eliminated in feces via biliary excretion.
Primarily renal excretion of unchanged drug and metabolites; approximately 80-90% of a dose is excreted in urine within 4-6 hours, with 50% as unchanged pralidoxime and the remainder as metabolites (e.g., 1-methyl-2-pyridone-2-aldoxime). Minor biliary/fecal elimination (<10%).
Category C
Category C
Antidote
Antidote